Business Wire

BearingPoint: New Mobility Players to Change the Competitive Landscape as Personal Mobility Shifts to Services From Ownership

Share

Management and technology consultancy BearingPoint’s latest study suggests mobility decisions will be very different by 2030. The study, “Destination 2030, Who’s in the driving seat for the future of mobility?” identified three trends that will drive mobility in the coming years:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005066/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Destination 2030 - who’s in the driving seat for the future of mobility? (Graphic: Business Wire)

1.) every journey will become a personalized experience

2.) climate neutrality will be non-negotiable – from the cradle to the grave

3.) users will consume services rather than own vehicles.

“It will be a radically different mobility ecosystem that will affect automotive manufacturers, transportation providers, and even energy suppliers as well as tech and insurance companies. What changes is how services are provided and consumed, and these industries must start preparing now. The growth of personalized mobility, mobility as a service and the push towards carbon-neutrality will all profoundly impact the way we think about travel. We’ll control our travel experiences in a new way, and this will impact our relationship with car brands, potentially weakening their ownership of us as customers,” said Dr. Stefan Penthin, global leader Automotive, Industrial Equipment & Manufacturing at BearingPoint.

Remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility

The study drew from BearingPoint’s internal research, the views of clients across all industry sectors and input from the consultancy’s sector and technology leaders. The study says remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility and the direction and pace of change.

“87% of the survey participants believe they will commute less frequently to work and 81% said they will take significantly fewer business trips compared to 2019, and if this trend continues, it will impact investment in infrastructure. The increased costs associated with developing new mobility infrastructure cannot be passed on entirely to the end user. Legislation may also need to be implemented to achieve the right infrastructure to support electric vehicles. Licensing and enforcement will shift focus from the individual to the provider,” said Andrew Montgomery, global leader Government and Public Sector at BearingPoint.

Three trends that will drive mobility in the coming years

The study sees every journey becoming a personalized experience. Public transportation will shift toward individual mobility, with schedules dictated by consumer needs, rather than predefined as with traditional public transportation. This will lead to more user-centric offerings, making traveling time more productive.

Climate neutrality will be non-negotiable, according to the study, which points to 80% of manufactured engines being green by 2030. Investment will increase in zero-impact modes and related infrastructure, particularly those that promote well-being, such as walking and cycling. And half of the participants (49%) say that they would sacrifice vehicle ownership to reduce their environmental footprint by 2030.

As users will consume services rather than own vehicles, they will switch to on-demand services rather than owning an underutilized vehicle. The services and software will be more important to the general consumer than the physical vehicle and brand, as software platforms will orchestrate the entire journey. 81% of participants point out that they will prefer to use one single app/platform for ordering and billing all their mobility-related services. The study also sees new entrants as constructors, not disruptors.

For more details, please read the full article here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030/

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alexander Bock
Global Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye